Literature DB >> 11857085

Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.

Martin Sattler1, Yuri B Pride, Laura R Quinnan, Shalini Verma, Nicole A Malouf, Hervé Husson, Ravi Salgia, Stanley Lipkowitz, James D Griffin.   

Abstract

CBL and the related CBL-B protein are two members of a family of RING finger type ubiquitin E3 ligases that are believed to function as negative regulators of signal transduction in hematopoietic and immune cells. In mice, expression of v-Cbl causes lymphomas, and targeted disruption of either the CBL gene or the CBL-B gene can result in a lymphoproliferative disorder or hypersensitivity of lymphocytes. CBL is one of the most prominent targets of the BCR/ABL tyrosine kinase oncogene. We compared the role of CBL and CBL-B in signal transduction of BCR/ABL using pairs of cell lines before and after expression of BCR/ABL. In contrast to CBL, BCR/ABL was found to rapidly downregulate the expression of CBL-B protein. The decrease in CBL-B protein induced by BCR/ABL was associated with downregulation of CBL-B mRNA. Downregulation and tyrosine phosphorylation of CBL-B required BCR/ABL kinase activity. However, despite their known similarities in structure and function, we found CBL and CBL-B proteins to be involved in distinct signaling complexes. CBL was predominantly in a complex with phosphatidylinositol 3'-kinase and CRKL, while CBL-B was not associated with any significant phosphatidylinositol 3'-kinase activity. A major CBL-B associated protein was identified as mono-ubiquitinated Vav, a nucleotide exchange factor for Rac1. These results demonstrate that BCR/ABL signals differentially through CBL and CBL-B, with downregulation of the CBL-B protein potentially contributing to BCR/ABL-mediated transformation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11857085     DOI: 10.1038/sj.onc.1205202

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  10 in total

Review 1.  Roles of E3 ubiquitin ligases in cell adhesion and migration.

Authors:  Cai Huang
Journal:  Cell Adh Migr       Date:  2010-01-18       Impact factor: 3.405

2.  Cbl-b promotes chemotherapy-induced apoptosis in rat basophilic leukemia cells by suppressing PI3K/Akt activation and enhancing MEK/ERK activation.

Authors:  Xiujuan Qu; Yingchun Li; Jing Liu; Ling Xu; Ye Zhang; Xuejun Hu; Kezuo Hou; Yunpeng Liu
Journal:  Mol Cell Biochem       Date:  2010-02-24       Impact factor: 3.396

3.  Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.

Authors:  Margret S Fernandes; Mamatha M Reddy; Nicole J Croteau; Christoph Walz; Henry Weisbach; Klaus Podar; Hamid Band; Martin Carroll; Andreas Reiter; Richard A Larson; Ravi Salgia; James D Griffin; Martin Sattler
Journal:  J Biol Chem       Date:  2010-07-09       Impact factor: 5.157

Review 4.  c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses.

Authors:  Christine B F Thien; Wallace Y Langdon
Journal:  Biochem J       Date:  2005-10-15       Impact factor: 3.857

5.  F604S exchange in FIP1L1-PDGFRA enhances FIP1L1-PDGFRA protein stability via SHP-2 and SRC: a novel mode of kinase inhibitor resistance.

Authors:  S P Gorantla; K Zirlik; A Reiter; C Yu; A L Illert; N Von Bubnoff; J Duyster
Journal:  Leukemia       Date:  2015-03-12       Impact factor: 11.528

6.  The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

Authors:  Gerlinde Wernig; Jeffrey R Gonneville; Brian J Crowley; Margret S Rodrigues; Mamatha M Reddy; Heidi E Hudon; Christoph Walz; Andreas Reiter; Klaus Podar; Yohan Royer; Stefan N Constantinescu; Michael H Tomasson; James D Griffin; D Gary Gilliland; Martin Sattler
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

Review 7.  E3 ubiquitin ligase Cbl-b in innate and adaptive immunity.

Authors:  Qingjun Liu; Hong Zhou; Wallace Y Langdon; Jian Zhang
Journal:  Cell Cycle       Date:  2014-05-14       Impact factor: 4.534

8.  Antitumoral effects of cyclin-dependent kinases inhibitors CR8 and MR4 on chronic myeloid leukemia cell lines.

Authors:  Samuel Troadec; Mélina Blairvacq; Nassima Oumata; Hervé Galons; Laurent Meijer; Christian Berthou
Journal:  J Biomed Sci       Date:  2015-07-17       Impact factor: 8.410

9.  Rs4911154 of circ-ITCH aggravated tumor malignancy of thyroid nodules via the circ-ITCH/miR-22-3p/CBL axis.

Authors:  Yiqing Guo; Hua Zheng; Jie Yin; Huaming Wang
Journal:  Sci Rep       Date:  2021-09-16       Impact factor: 4.379

10.  Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function.

Authors:  Daniel Trageser; Ilaria Iacobucci; Rahul Nahar; Cihangir Duy; Gregor von Levetzow; Lars Klemm; Eugene Park; Wolfgang Schuh; Tanja Gruber; Sebastian Herzog; Yong-mi Kim; Wolf-Karsten Hofmann; Aihong Li; Clelia Tiziana Storlazzi; Hans-Martin Jäck; John Groffen; Giovanni Martinelli; Nora Heisterkamp; Hassan Jumaa; Markus Müschen
Journal:  J Exp Med       Date:  2009-07-20       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.